Advanced hepatocellular carcinoma
Conditions
Interventions
Combination chemotherapy with Peg-Interferon and oral Tegafur/Uracil
Sponsors
The third department of Internal Medicine, Wakayama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or clinically confirmed hepatocellular carcinoma 2)Measurable and hypervascular hepatocellular carcinoma on contrast CT 3)No indication or resistance hepatic resection and percutaneous treatment 4)No tumor thrombus in main portal vein 5)Child-Pugh score of A or B 6)Adequate bone marrow function 7)Ages 20years and above,under 80 years 8)Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 9)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Allergic reaction to IFN and/or UFT 2)Positive by prick test of IFN 3)Severe liver damage after TAE 4)Autoimmune disease 5)Depression or mental neuropathic illness 6)Uncontrolled heart or renal desease 7)Pregnant or nursing 8)Extensive leukopenia or extensive thrombocytopia 9)Use Sho-saiko-to 10)Other uncontrolled severe illness 11)Other inappropriate patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety profile | — |
Countries
Japan
Contacts
Public ContactHiroki Ueda
Wakayama Medical University The third department of Internal Medicine
Outcome results
None listed